News & Videos - OBSEVA SA

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company (Swiss Security Number 126'004'193 / ISIN CH1260041939) from SIX Swiss Exchange and has exempted the company from certain obligations associated with...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurrent to the decision to wind-down the company’s operations, Catarina Edfjäll, Ph.D. has decided to step down from the Board effective today. “We would like to warmly thank Catarina for her significant contribution to the company over...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operations with the termination of all of its employees, including Fabien de Ladonchamps, CEO, and notified SIX Swiss Exchange's listing authority that there was a substantial risk that it will lack the resources to have financial statements for...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it was granted a temporary moratorium ( sursis provisoire ) by the competent court in Geneva, Switzerland. The Tribunal de première instance of Geneva granted the requested moratorium for a period of four months ending 29 May 2024 and appointed a commissioner (...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that, following a comprehensive assessment of the company's financial position, the Board of Directors has opted to seek a moratorium from the competent court in Geneva, Switzerland. The moratorium, if granted, will provide essential protection, enabling the company to...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that XOMA will be receiving full worldwide rights on ebopiprant, an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist, following the termination of the license agreement with Organon. After positive Phase 2a results in November...

ObsEva Files half Year 202 3 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerlan d – September 27 , 202 3 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today published its Half Year 2023 Financial Statements. The Half Year 2023 Financial Statements may be found on the financial section of the Company’s website, he r e or directly via the...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – Ju ly 13 , 202 3 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it has recovered full worldwide rights on nolasiban, a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing embryo transfer after in vitro fertilization (“IVF”), following the termination...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 8 , 202 3 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today published the invitation to its 2023 Annual General Meeting of Shareholders to be held on June 29, 2023, at 10:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3 rd floor, 1228 Plan-les-Ouates, Switzerland. The agenda of the meeting will be as follows: 1 Approval of...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2 , 202 3 – ObsEva SA ( SIX: OBSN ) , a biopharmaceutical company developing novel therapies for women’s health, today announced that Fabien de Ladonchamps has been appointed Chief Executive Officer effective May 1, 2023. Mr. de Ladonchamps succeeds Will Brown who previously held the position of Interim Chief Executive Officer and Chief Financial Officer. Mr. Brown, who leaves his functions and...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20 , 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF ), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that it intends for its common shares to be traded under a new International Securities Identification Numbers (“ISIN”) beginning on April 25, 2023. End of DTC Eligibility and Move to SIX SIS ObsEva's common shares were...

ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31 , 2023 – ObsEva SA ( SIX: OBSN / OTC Pink Market : OBSVF ), a biopharmaceutical company developing and commercializing novel therapies to improve women’s health, today published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022. The U.S. Annual Report on Form 10-K can be...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 1 5 , 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that it received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13 , 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced a strategic reorganization that will consolidate operations in Switzerland so as to preserve cash, focus resources towards the development of nolasiban, a novel, oral oxytocin receptor agonist to improve in vitro fertilization success...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the competent court in Geneva, Switzerland has granted the Company’s request to withdraw its moratorium considering that the Company is no longer over-indebted. The Company resolved its over-indebtedness due to the previously...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 14 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today announced an update on its progress towards meeting Nasdaq’s minimum stockholders’ equity requirement. As previously announced, on August 19, 2022, the Company received a letter (the “Nasdaq Letter”) from the Nasdaq Stock...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that its board of directors approved on December 8, 2022 an increase of its share capital through the issuance of 20,000,000 newly registered shares at an issue price of 1/13 of a Swiss Franc each. The 20,000,000 new shares, to be...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 1 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (“ObsEva” or the “Company”), a biopharmaceutical company developing novel therapies for women’s health, today reported financial results for the third quarter ended September 30, 2022 and provided a business update. “We are pleased to have neared the completion of a restructuring process that allowed us to generate an important influx...

Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 million The sale proceeds are expected to enable ObsEva to resolve its current over-indebtedness position and to withdraw its pending Swiss moratorium proceedings Sale proceeds expected to position ObsEva to satisfy Nasdaq stockholders’ equity requirement for continued public listing ObsEva expects to have greater than one year of cash runway, providing...